Trisalus Life Sciences Inc. will host a virtual key opinion leader event on November 12, 2025, to discuss the TriNav Infusion System for the treatment of uterine fibroids. The event will feature an overview of the TriNav Infusion System's pressure-enabled drug delivery approach and review the uterine artery embolization market landscape.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.
Comments